التفاصيل البيبلوغرافية
| العنوان: |
COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. |
| المؤلفون: |
Fan, Bingwen Eugene, Ng, Jensen, Chan, Stephrene Seok Wei, Christopher, Dheepa, Tso, Allison Ching Yee, Ling, Li Min, Young, Barnaby Edward, Wong, Lester Jun Long, Sum, Christina Lai Lin, Tan, Hwee Tat, Ang, Mui Kia, Lim, Gek Hsiang, Ong, Kiat Hoe, Kuperan, Ponnudurai, Chia, Yew Woon |
| المصدر: |
Journal of Thrombosis & Thrombolysis; Apr2021, Vol. 51 Issue 3, p663-674, 12p |
| مستخلص: |
Patients with COVID-19 are known to be at risk of developing both venous, arterial and microvascular thrombosis, due to an excessive immuno-thrombogenic response to the SARS-CoV-2 infection. Overlapping syndromes of COVID-19 associated coagulopathy with consumptive coagulopathy and microangiopathy can be seen in critically ill patients as well. Blood was collected from 12 Intensive Care Unit (ICU) patients with severe COVID-19 who were on either mechanical ventilation or on high flow oxygen with a PaO2/FiO2 ratio of <300 mmHg. Laboratory tests were performed for parameters of haemostasis, clot waveform analysis and anti-phospholipid antibodies. CWA parameters were raised with elevated aPTT median Min1 (clot velocity) 9.3%/s (IQR 7.1–9.9%/s), elevated PT median Min1 10.3%/s (IQR 7.1–11.1%/s), elevated aPTT median Min2 (clot acceleration) 1.5%/s2 (IQR 1.0–1.6%/s2), elevated PT median Min2 5.2%/s2 (3.6–5.7%/s2), elevated aPTT median Max2 (clot deceleration) 1.3%/s2 (IQR 0.8–1.4%/s2) elevated PT median Max2 3.8%/s2 (IQR 2.6–4.2%/s2), increased aPTT median Delta change (decreased light transmission due to increased clot formation) 87.8% (IQR 70.2–91.8%) and PT median Delta change 33.0%. This together with raised median Factor VIII levels of 262.5%, hyperfibrinogenemia (median fibrinogen levels 7.5 g/L), increased median von Willebrand factor antigen levels 320% and elevated median D-dimer levels 1.7 μg/dl support the diagnosis of COVID-19 associated coagulopathy. A lupus anticoagulant was present in 50% of patients. Our laboratory findings further support the view that severe SARS-CoV-2 infection is associated with a state of hypercoagulability. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Thrombosis & Thrombolysis is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
